Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main Rhythm Pharmaceuticals, Inc. Transaction History

Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main

$92.1 Billion
Q2 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2018 Aug 14, 2018	SELL	$17.02 - $35.2 $285,936 - $591,360	-16,800 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$19.9 - $32.25 $334,320 - $541,800	16,800 New	16,800 $334,000

Others Institutions Holding RYTM

# of Institutions

178

Shares Held

69.1M

Call Options Held

467K

Put Options Held

224K

Primecap Management CO Pasadena, CA

7.31M
Shares

$375 Million
0.22% of portfolio
Black Rock Inc. New York, NY

6.74M
Shares

$346 Million
0.01% of portfolio
Baker Bros. Advisors LP New York, NY

6.4M
Shares

$329 Million
3.49% of portfolio
Ra Capital Management, L.P. Boston, MA

6.08M
Shares

$312 Million
3.77% of portfolio
Goldman Sachs Group Inc New York, NY

5.29M
Shares

$272 Million
0.04% of portfolio

View Full List

About RHYTHM PHARMACEUTICALS, INC.

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $2.86B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

More about RYTM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main, based on Form 13F filings with the SEC.

News

Stay updated on Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main with notifications on news.

Account